S Silberstein

Summary

Affiliation: Thomas Jefferson University
Country: USA

Publications

  1. Parikh S, Silberstein S. Current Status of Antiepileptic Drugs as Preventive Migraine Therapy. Curr Treat Options Neurol. 2019;21:16 pubmed publisher
    ..Further studies are needed to determine the efficacy of the newer AEDs, zonisamide and levetiracetam, in migraine prevention and to clarify the role of gabapentinoids in headache management. ..
  2. Silberstein S. Treatment recommendations for migraine. Nat Clin Pract Neurol. 2008;4:482-9 pubmed publisher
    ..Preventive treatments are selected on the basis of the drugs' side-effect profiles and the patient's coexistent and comorbid conditions. ..
  3. request reprint
    Silberstein S, Stark S, Lucas S, Christie S, Degryse R, Turkel C. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2005;80:1126-37 pubmed
    ..The placebo response was higher than expected. BoNTA was safe and well tolerated. Further study of BoNTA prophylactic treatment of CDH appears warranted. ..
  4. Silberstein S, Mannix L, Goldstein J, Couch J, Byrd S, Ames M, et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology. 2008;71:114-21 pubmed publisher
    ..The fixed-dose single-tablet formulation of sumatriptan/naproxen was effective and well tolerated in an early intervention paradigm for the acute treatment of migraine, including traditional and nontraditional symptoms. ..
  5. Silberstein S, Schoenen J, Gobel H, Diener H, Elkind A, Klapper J, et al. Tonabersat, a gap-junction modulator: efficacy and safety in two randomized, placebo-controlled, dose-ranging studies of acute migraine. Cephalalgia. 2009;29 Suppl 2:17-27 pubmed publisher
    ..Based on the pharmacokinetics and actions on cortical spreading depression, tonabersat may have potential value in migraine prophylaxis. ..
  6. Silberstein S, Newman L, Marmura M, Nahas S, Farr S. Efficacy endpoints in migraine clinical trials: the importance of assessing freedom from pain. Curr Med Res Opin. 2013;29:861-7 pubmed publisher
    ..The measures of pain-free response 2 hours postdose and sustained pain-free response can differentiate among treatments and be used to guide therapeutic choices. ..
  7. Silberstein S, Marcus D. Sumatriptan : treatment across the full spectrum of migraine. Expert Opin Pharmacother. 2013;14:1659-67 pubmed publisher
    ..This article develops a treatment algorithm that offers suggested roles for different formulations of sumatriptan based on attack severity and response to initial sumatriptan therapy. ..
  8. Yuan H, Hopkins M, Goldberg J, Silberstein S. Single-item migraine screening tests, self-reported bothersome headache or stripe pattern hypersensitivity?. Acta Neurol Scand. 2016;134:277-83 pubmed publisher
    ..64 [95% CI 0.56-0.72]). When performed in an OB/GYN clinic, self-reported bothersome HA question seemed more powerful than visual stripe pattern test in screening migraine thus could potentially be used as a single-item screening test. ..
  9. request reprint
    Silberstein S, Elkind A, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63:261-9 pubmed
    ..The findings are consistent with the long duration of action and good tolerability of frovatriptan observed in short-term migraine management. ..

More Information

Publications15

  1. Silberstein S, Saper J, Berenson F, Somogyi M, McCague K, D Souza J. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology. 2008;70:548-55 pubmed publisher
    ..5%); no adverse event occurred in more than 15% of the placebo-treated patients. Overall, oxcarbazepine was safe and well tolerated; however, oxcarbazepine did not show efficacy in the prophylactic treatment of migraine headaches. ..
  2. Silberstein S, Dodick D, Saper J, Huh B, Slavin K, Sharan A, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2012;32:1165-79 pubmed publisher
    ..Clinical trials.gov (NCT00615342). ..
  3. Silberstein S, Vodovskaia N. Trigeminal autonomic cephalalgias other than cluster headache. Med Clin North Am. 2013;97:321-8 pubmed publisher
    ..SUNCT is a subtype of SUNA in which both conjunctival injection and tearing are present. SUNA differs from SUNCT in that autonomic symptoms are less prominent. ..
  4. Silberstein S, Calhoun A, Lipton R, Grosberg B, Cady R, Dorlas S, et al. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. Neurology. 2016;87:529-38 pubmed publisher
    ..This pilot study lacked the precision to exclude important safety issues or benefits of nVNS. ..
  5. Silberstein S, Mechtler L, Kudrow D, Calhoun A, McClure C, Saper J, et al. Non-Invasive Vagus Nerve Stimulation for the ACute Treatment of Cluster Headache: Findings From the Randomized, Double-Blind, Sham-Controlled ACT1 Study. Headache. 2016;56:1317-32 pubmed publisher
    ..This safe and well-tolerated treatment represents a novel and promising option for eCH. ClinicalTrials.gov identifier: NCT01792817. ..
  6. Yuan H, Lauritsen C, Kaiser E, Silberstein S. CGRP Monoclonal Antibodies for Migraine: Rationale and Progress. BioDrugs. 2017;31:487-501 pubmed publisher
    ..CGRP function-blocking mAbs may potentially revolutionize the management of migraine. This review discusses in depth the fundamental role of CGRP in migraine pathogenesis as well as the clinical efficacy of CGRP function-blocking mAbs. ..